The DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index.
Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the Surveillance, Epidemiology, and End Results Program
Open accessAbstract
BACKGROUND: Osteosarcoma, which is the most common primary bone tumor, occurs most frequently in adolescents, but there is a second incidence peak among individuals aged >60 years. Most osteosarcoma epidemiology studies have been embedded in large analyses of all bone tumors or focused on cases occurring in adolescence. Detailed descriptions of osteosarcoma incidence and survival with direct comparisons among patients of all ages and ethnicities are not available. METHODS: Frequency, incidence, and survival rates for 3482 patients with osteosarcoma from the National Cancer Institute's population‐based Surveillance, Epidemiology, and End Results (SEER) Program between 1973 and 2004 were investigated by age (ages 0‐24 years, 25‐59 years, and 60 to ≥85 years), race, sex, pathology subtype, stage, and anatomic site. RESULTS: There were large differences in incidence and survival rates by age. There was a high percentage of osteosarcoma with Paget disease and osteosarcoma as a second or later cancer among the elderly. There was a high percentage of osteosarcoma among patients with Paget disease and osteosarcoma as a second or later cancer among the elderly. Tumor site differences among age groups were noted. Survival rates varied by anatomic site and disease stage and did not improve significantly from 1984 to 2004. CONCLUSIONS: This comprehensive, population‐based description of osteosarcoma, identified important differences in incidence, survival, pathologic subtype, and anatomic site among age groups, and quantified the impact of osteosarcoma in patients with Paget disease or as a second cancer on incidence and mortality rates. These findings may have implications in understanding osteosarcoma biology and epidemiology. Cancer 2009. © 2009 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Osteosarcoma is the most common primary malignant tumour of the bone.”
From Osteosarcoma (2022) · cites this paper as [1]
In the citing paper
“higher rates of osteosarcoma have been observed in African American children and young adults in the USA than in white individuals 1 .”
From Osteosarcoma (2022) · cites this paper as [1]
In the citing paper
“Osteosarcoma incidence is bimodal, peaking at 18 and 60 years of age”
From Osteosarcoma (2022) · cites this paper as [1]
In the citing paper
“Osteosarcoma incidence has a bimodal age distribution with a primary peak in adolescents and young adults and a second, smaller peak in the seventh and eighth decade of life 1”
From Osteosarcoma (2022) · cites this paper as [1]
In the citing paper
“In the USA, osteosarcoma accounts for <1% of all new cancer diagnoses with ~1,000 new cases diagnosed per year, half of these cases occurring in children and adolescents 1 .”
From Osteosarcoma (2022) · cites this paper as [1]
In the citing paper
“Some studies suggested that the histological subtype of osteosarcoma can influence the degree of necrosis, with chondroblastic and telangiectatic subtypes having less necrosis but those differences have not translated into improvement in survival 1,118 .”
From Osteosarcoma (2022) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
World Health Organization Classification of Tumours
Fletcher, C., van den Berg, A., & Molenaar, I. (2002) · Cited by 7,079
International Classification of Diseases for Oncology
National Cancer Institute (2020) · Definitions · doi:10.32388/1bjeus · Cited by 3,810
Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995
(1999) · PsycEXTRA Dataset · doi:10.1037/e407432005-001 · Cited by 1,933
The international incidence of childhood cancer
Parkin, D. M., Stiller, C. A., Draper, G. J., & Bieber, C. A. (1988) · International Journal of Cancer · doi:10.1002/ijc.2910420408 · Cited by 1,022
Trends in childhood cancer incidence in the U.S. (1992–2004)
Linabery, A. M., & Ross, J. A. (2007) · Cancer · doi:10.1002/cncr.23169 · Cited by 644
Bleyer, A., O’Leary, M., Barr, R. D., & Ries, L. A. G. (2006) · Cited by 619
Osteosarcoma, Chondrosarcoma, and Ewing's Sarcoma
Damron, T. A., Ward, W. G., & Stewart, A. K. (2007) · Clinical Orthopaedics and Related Research · doi:10.1097/blo.0b013e318059b8c9 · Cited by 530
Osteogenic sarcoma. A study of six hundred cases.
Dahlin, D. C., & Coventry, M. B. (1967) · PubMed · Cited by 475
Bone Tumors: General Aspects and Data on 8,542 Cases
Spjut, H. J. (1987) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)61914-4 · Cited by 455
Dahlin, D. C., & Coventry, M. B. (1967) · Journal of Bone and Joint Surgery · doi:10.2106/00004623-196749010-00008 · Cited by 453
Flagged first, then by citations
2 of the 52 references couldn’t be matched to a known paper.
Research works printed but not linked: 12
- 10.1002/1097-0142(19950101)75:1 <203::AID-CNCR2820751308>3.0.CO;2-V · DOI
- Dorfman HA, 1997, Bone Tumors
- Murray RO, 1975, A Textbook of Radiology, 109
- Hanson MR, 1982, Epidemiology of Cancer in the Young
- 10.1002/1097-0142(19860715)58:2 <598::AID-CNCR2820581332>3.0.CO;2-C · DOI
- Surveillance, Epidemiology, and End Results Program of the National Cancer Institute, 2007, SEER Registries: Surveillance Research Program, National Cancer Institute
- Surveillance Research Program, 2007, National Cancer Institute SEER*Stat Software, version 6.3.6
- Day JC, 1996, Population Projections of the United States by Age, Sex, Race and Hispanic Origin, 1995 to 2050, US Bureau of the Census, Current Population Reports, P25‐1130
- Surveillance, Epidemiology, and End Results (SEER) Program, 2007, SEER*Stat Database: Incidence‐SEER 13 Regs Limited‐Use, November 2006 Submission (1992‐2004)‐Linked to County Attributes‐Total US, 1969‐2004 Counties
- Surveillance, Epidemiology, and End Results (SEER) Program, 2007, SEER*Stat Database: Incidence‐SEER 9 Regs Limited‐Use, November 2006 Submission (1973‐2004)‐Linked to County Attributes‐Total US, 1969‐2004 Counties
- Surveillance, Epidemiology, and End Results (SEER) Program, 2007, SEER*Stat Database: Incidence‐SEER 17 Regs Limited‐Use, November 2006 Submission (1973‐2004 varying)‐Linked to County Attributes‐Total US, 1969‐2004 Counties
- Aegerter E, 1975, Orthopedic Disease
Cited by
Sorted by citations
Items 201–300 of 1,002
Bhattacharya, S., Chalk, A. M., Ng, A. J. M., Martin, T. J., Zannettino, A. C. W., Purton, L. E., Lü, J., Baker, E. K., & Walkley, C. R. (2016) · Oncogene · doi:10.1038/onc.2016.68 · Cited by 72
Cisplatin selects for stem-like cells in osteosarcoma by activating Notch signaling
Yu, L., Fan, Z., Fang, S., Yang, J., Gao, T., Simões, B. M., Eyre, R., Guo, W., & Clarke, R. B. (2016) · Oncotarget · doi:10.18632/oncotarget.8849 · Cited by 72
A causal role for circulating miR-34b in osteosarcoma
Tian, Q., Jia, J., Ling, S., Liu, Y., Yang, S., & Shao, Z. (2013) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2013.08.024 · Cited by 71
Targeting the Wnt/β-catenin pathway in human osteosarcoma cells
Fang, F., VanCleave, A. M., Helmuth, R., de Oliveira, H. T., Rickel, K., Wollenzien, H., Sun, H., Zeng, E., Zhao, J., & Tao, J. (2018) · Oncotarget · doi:10.18632/oncotarget.26377 · Cited by 71
Katonis, P., Datsis, G., Karantanas, A. H., Kampouroglou, A., Lianoudakis, S., Licoudis, S., Papoutsopoulou, E., & Alpantaki, K. (2013) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s10099 · Cited by 74
Kong, D., & Wang, Y. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26273 · Cited by 70
RetractedOsteosarcoma: Current Concepts and Evolutions in Management Principles
Pilavaki, P., Ardakani, A. H. G., Gikas, P. D., & Constantinidou, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082785 · Cited by 70
The role of the CXCL12-CXCR4/CXCR7 axis in the progression and metastasis of bone sarcomas (Review)
Liao, Y., Zhou, C., Zeng, H. M., Zuo, D., Wang, Z., YIN, F., HUA, Y.-Q., & CAI, Z.-D. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1521 · Cited by 70
Pan, Z., Cheng, D., Wei, X., Li, S.-J., Guo, H., & Yang, Q. (2021) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2020.117596 · Cited by 69
Gupte, A., Baker, E. K., Wan, S.-S., Stewart, E. A., Loh, A. H. P., Shelat, A. A., Gould, C. M., Chalk, A. M., Taylor, S., Lackovic, K., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3026 · Cited by 70
Han, K., Zhao, T., Chen, X., Bian, N., Yang, T.-T., Ma, Q., Cai, C., Fan, Q., Zhou, Y., & Ma, B. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2571 · Cited by 68
Recent advances in understanding the molecular basis of Paget disease of bone
Goode, A., & Layfield, R. (2009) · Journal of Clinical Pathology · doi:10.1136/jcp.2009.064428 · Cited by 68
Yu, L., Zhang, J., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.871076 · Cited by 68
Meta-analysis of serum lactate dehydrogenase and prognosis for osteosarcoma
Fu, Y., Lan, T., Cai, H., Lu, A., & Yu, W. (2018) · Medicine · doi:10.1097/md.0000000000010741 · Cited by 68
Gongyi, L., Miao, J., & Zhang, X. (2017) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504017x14920318811721 · Cited by 67
Yue, Z., Guan, X., Chao, R., Huang, C., Li, D., Yang, P., Liu, S., Hasegawa, T., Guo, J., & Li, M. (2019) · Molecules · doi:10.3390/molecules24142665 · Cited by 67
Sun, X., Geng, X., Zhang, J., & Zhang, C. (2014) · Tumor Biology · doi:10.1007/s13277-014-2822-z · Cited by 67
Jiang, R., Zhang, C., Liu, G., Gu, R., & Wu, H. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26024 · Cited by 66
RetractedThe management of adolescents and young adults with cancer
Hughes, N., & Stark, D. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.05.001 · Cited by 66
Zhang, H., Yan, J., Lang, X., & Zhuang, Y. (2018) · Oncology Letters · doi:10.3892/ol.2018.9410 · Cited by 66
Guenther, L. M., Rowe, R. G., Acharya, P. T., Swenson, D. W., Meyer, S. C., Clinton, C. M., Guo, D., Sridharan, M., London, W. B., Grier, H. E., et al. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26896 · Cited by 66
Zhang, L., Lv, Z., Xu, J., Chen, C., Ge, Q., Li, P., Wei, D., Wu, Z., & Sun, X. (2018) · FEBS Journal · doi:10.1111/febs.14416 · Cited by 67
Sun, Y., Liu, L., Wang, Y., He, A., Hu, H., Zhang, J. J., Han, M., & Huang, Y. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s172909 · Cited by 66
Zhang, T., Li, S., Li, J., Yin, F., Hua, Y., Wang, Z., Lin, B., Wang, H., Zou, D., Zhou, Z., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.305 · Cited by 65
RetractedLncRNA DLX6-AS1/miR-129-5p/DLK1 axis aggravates stemness of osteosarcoma through Wnt signaling
Zhang, R., Tang, T., Yu, H., & Yao, X. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.11.019 · Cited by 65
MicroRNA-Based Diagnosis and Treatment of Metastatic Human Osteosarcoma
Sasaki, R., Osaki, M., & Okada, F. (2019) · Cancers · doi:10.3390/cancers11040553 · Cited by 66
Osteosarcoma in very young children
Kager, L., Zoubek, A., Dominkus, M., Lang, S., Bodmer, N., Jundt, G., Klingebiel, T., Jürgens, H., Gadner, H., Bielack, S., et al. (2010) · Cancer · doi:10.1002/cncr.25287 · Cited by 65
Quartuccio, N., Treglia, G., Salsano, M., Mattoli, M. V., Muoio, B., Piccardo, A., Lopci, E., & Cistaro, A. (2013) · Radiology and Oncology · doi:10.2478/raon-2013-0017 · Cited by 65
Huang, X., Hu, H., Zhang, W., & Shao, Z. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28476 · Cited by 67
Palmerini, E., Agostinelli, C., Picci, P., Pileri, S. A., Marafioti, T., Lollini, P., Scotlandi, K., Longhi, A., Benassi, M. S., & Ferrari, S. M. (2017) · Oncotarget · doi:10.18632/oncotarget.22912 · Cited by 66
Targeting CD44 by CRISPR-Cas9 in Multi-Drug Resistant Osteosarcoma Cells
Zheng, X. W., Wan, J., Nur, A. A., Dou, P., Mankin, H. J., Liu, T., & Ouyang, Z. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000495714 · Cited by 64
Zhao, Y., Tu, M., Yu, Y.-F., Wang, W.-P., Chen, Q., Qiu, J.-X., Yu, A.-X., & Yu, A. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.10.015 · Cited by 66
Detection of circulating tumor DNA in patients with osteosarcoma
Barris, D. M., Weiner, S. B., Dubin, R. A., Fremed, M., Zhang, X., Piperdi, S., Zhang, W., Maqbool, S., Gill, J., Roth, M., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24268 · Cited by 63
Systematic Review of Recurrent Osteosarcoma Systemic Therapy
Gazouli, I., Kyriazoglou, A., Kotsantis, I., Anastasiou, M., Pantazopoulos, A., Prevezanou, M., Chatzidakis, I., Kavourakis, G., Economopoulou, P., Kontogeorgakos, V., et al. (2021) · Cancers · doi:10.3390/cancers13081757 · Cited by 63
Mesenchymal Stem Cells and Extracellular Vesicles in Osteosarcoma Pathogenesis and Therapy
Sarhadi, V. K., Daddali, R., & Seppänen-Kaijansinkko, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011035 · Cited by 63
Strategies for the targeted delivery of therapeutics for osteosarcoma
Hughes, D. P. M. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903280422 · Cited by 63
miR-17 inhibitor suppressed osteosarcoma tumor growth and metastasis via increasing PTEN expression
Gao, Y., Luo, L., Li, S., & Cao, Y. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.01.061 · Cited by 63
The Immune Landscape of Osteosarcoma: Implications for Prognosis and Treatment Response
Cascini, C., & Chiodoni, C. (2021) · Cells · doi:10.3390/cells10071668 · Cited by 63
Thayanithy, V., Park, C., Sarver, A. L., Kartha, R. V., Korpela, D. M., Graef, A. J., Steer, C. J., Modiano, J. F., & Subramanian, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043720 · Cited by 63
Age-Period-Cohort Analysis of Primary Bone Cancer Incidence Rates in the United States (1976–2005)
Anfinsen, K. P., Devesa, S. S., Bray, F., Troisi, R. J., Jónasdóttir, T. J., Bruland, Ø. S., & Grotmol, T. (2011) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-11-0136 · Cited by 65
Self-citationPaget's Disease of Bone: Evidence for Complex Pathogenetic Interactions
Chung, P. Y. J., & Hul, W. V. (2011) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2011.07.005 · Cited by 63
Ye, Z., Jingzhong, L., Yangbo, L., Lei, C., & Jiandong, Y. (2014) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504014x13890370410203 · Cited by 63
Proteomic research in sarcomas – current status and future opportunities
Burns, J., Wilding, C. P., Jones, R. L., & Huang, P. H. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.11.003 · Cited by 62
Hingorani, P., Maas, M. L., Gustafson, M. P., Dickman, P. S., Adams, R. H., Watanabe, M., Eshun, F., Williams, J., Seidel, M. J., & Dietz, A. B. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0082-0 · Cited by 62
Yang, J., Lin, C., Hsieh, Y., Cheng, H.-L., Lue, K., Yang, S., & Lu, K. (2013) · Food and Chemical Toxicology · doi:10.1016/j.fct.2013.06.028 · Cited by 62
TNFα promotes osteosarcoma progression by maintaining tumor cells in an undifferentiated state
Mori, T., Sato, Y., Miyamoto, K., Kobayashi, T., Shimizu, T., Kanagawa, H., Katsuyama, E., Fujie, A., Wu, H., Tando, T., et al. (2013) · Oncogene · doi:10.1038/onc.2013.545 · Cited by 62
Drugs in early clinical development for the treatment of osteosarcoma
Heymann, M., Brown, H. K., & Heymann, D. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1237503 · Cited by 65
Chemotherapy in head and neck osteosarcoma: Adjuvant chemotherapy improves overall survival
Chen, Y., Gokavarapu, S., Shen, Q., Liu, F., Cao, W., Ling, Y.-H., & Ji, T. (2017) · Oral Oncology · doi:10.1016/j.oraloncology.2017.08.017 · Cited by 62
Bientinesi, E., Lulli, M., Becatti, M., Ristori, S., Margheri, F., & Monti, D. (2022) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2022.111689 · Cited by 61
Polo-Like Kinase 4’s Critical Role in Cancer Development and Strategies for Plk4-Targeted Therapy
Zhang, X., Wei, C., Liang, H., & Han, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.587554 · Cited by 61
Bansal, P., Gehlot, K., Singhal, A., & Gupta, A. (2022) · Multimedia Tools and Applications · doi:10.1007/s11042-022-11949-6 · Cited by 63
Ryu, K., Susa, M., Choy, E., Cao, Y., Hornicek, F. J., Mankin, H. J., & Duan, Z. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-187 · Cited by 61
The role of pharmacogenetics in the treatment of osteosarcoma
Vos, H. I., Coenen, M. J. H., Guchelaar, H., & Loo, D. M. W. M. T. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.06.022 · Cited by 61
Carbon ion radiotherapy for inoperable pediatric osteosarcoma
Mohamad, O., the Working Group for Bone and Soft Tissue Sarcoma, Imai, R., Kamada, T., Nitta, Y., & Araki, N. (2018) · Oncotarget · doi:10.18632/oncotarget.25165 · Cited by 61
Increased survival of patients aged 0‐29 years with osteosarcoma: A period analysis, 1984‐2013
Wu, J., Sun, H., Li, J., Guo, Y., Zhang, K., Lang, C., Zou, C., & Ma, H. (2018) · Cancer Medicine · doi:10.1002/cam4.1659 · Cited by 61
The lnc RNA HNF 1A‐ AS 1 is a negative prognostic factor and promotes tumorigenesis in osteosarcoma
Cai, L., Lv, J., Zhang, Y., Li, J., Wang, Y., & Yang, H. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12944 · Cited by 60
Chu, X., Zhang, L., Li, Y., He, Y. H., Zhang, Y. X., & Du, C. (2022) · Small · doi:10.1002/smll.202205414 · Cited by 60
Liao, D., Zhong, L., Yin, J., Zeng, C., Wang, X., Huang, X., Chen, J., Zhang, H., Zhang, R., Guan, X., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0522-z · Cited by 60
RetractedHigh Expression of HULC Is Associated with Poor Prognosis in Osteosarcoma Patients
Uzan, V. R. M., Lengert, A. V. H., Boldrini, É., Penna, V., Scapulatempo‐Neto, C., Scrideli, C. A., Filho, A. P. D. M., Cavalcante, C. E. B., de Oliveira, C. Z., Lopes, L. F., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156774 · Cited by 59
Duong, L. M., & Richardson, L. C. (2013) · PubMed · Cited by 59
Zhang, Y., Sun, S., Chen, J., Ren, P., Hu, Y., Cao, Z., Sun, H., & Ding, Y. (2013) · Tumor Biology · doi:10.1007/s13277-013-1223-z · Cited by 59
Martín‐Broto, J., Redondo, A., Valverde, C. M., Vaz, M. A., Mora, J., del Muro, X. G., Gutierrez, A. M., Tous, C., Carnero, A., Marcilla, D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx536 · Cited by 59
Current Treatment Considerations for Osteosarcoma Metastatic at Presentation
Tsukamoto, S., Errani, C., Angelini, A., & Mavrogenis, A. F. (2020) · Orthopedics · doi:10.3928/01477447-20200721-05 · Cited by 59
Genomics and the Immune Landscape of Osteosarcoma
Wu, C.-C., & Livingston, J. A. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-43085-6_2 · Cited by 58
Lu, K., Su, S., Lin, C., Hsieh, Y., Lin, Y., Chien, M., Reiter, R. J., & Yang, S. (2018) · Journal of Pineal Research · doi:10.1111/jpi.12507 · Cited by 58
Chang, J., Wang, H., Wang, X., Zhao, Y., Zhao, D., Wang, C., Li, Y., Yang, Z., Lu, S., Zeng, Q., et al. (2015) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2015.05.006 · Cited by 58
The relationship between the expression of Ki-67 and the prognosis of osteosarcoma
Zeng, M., Zhou, J., Wen, L., Zhu, Y., Luo, Y., & Wang, W. (2021) · BMC Cancer · doi:10.1186/s12885-021-07880-y · Cited by 58
Diagnostic and prognostic potentials of microRNA-27a in osteosarcoma
Tang, J., Zhao, H., Cai, H., & Wu, H. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.01.025 · Cited by 58
Jerez, S., Araya, H., Hevia, D., Irarrázaval, C. E., Thaler, R., van Wijnen, A. J., & Galindo, M. A. (2019) · Gene · doi:10.1016/j.gene.2019.06.005 · Cited by 58
Monteiro, C. F., Custódio, C. A., & Mano, J. F. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.07.034 · Cited by 57
Song, B. S., Seo, J., Kim, D. H., Lim, J. S., Yoo, J. Y., & Lee, J. A. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25035 · Cited by 57
Liao, Y., Fu, Z., Zhou, C., Shan, L., Wang, Z., YIN, F., Zheng, L., Hua, Y., & CAI, Z.-D. (2015) · Oncology Reports · doi:10.3892/or.2015.3992 · Cited by 57
Deletion of the WWOX gene and frequent loss of its protein expression in human osteosarcoma
Yang, J., Cogdell, D. E., Yang, D., Hu, L., Li, H., Zheng, H., Du, X., Pang, Y., Trent, J. C., Chen, K., et al. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.09.018 · Cited by 57
A porcine model of osteosarcoma
Saalfrank, A., Janssen, K., Ravon, M., Flisikowski, K., Eser, S., Steiger, K., Flisikowska, T., Müller-Fliedner, P., Schulze, É. A., Brönner, C., et al. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.19 · Cited by 58
Antitumor functions and mechanisms of nitidine chloride in human cancers
Cui, Y., Wu, L., Cao, R., Xu, H., Xia, J., Wang, Z. P., & Ma, J. (2019) · Journal of Cancer · doi:10.7150/jca.37890 · Cited by 57
Song, Q., Shi, Z., Zhang, Y., Ji, L., Wang, K., Duan, D., & Dang, X. (2014) · Oncology Reports · doi:10.3892/or.2014.2989 · Cited by 56
Meng, C., Zhao, Z., Bai, R., Zhao, W., Wang, Y., Xue, H., Sun, L., Sun, C., Feng, W., & Guo, S. (2020) · Oncology Reports · doi:10.3892/or.2020.7492 · Cited by 56
Gemoll, T., Epping, F., Heinrich, L., Fritzsche, B., Roblick, U. J., Szymczak, S., Hartwig, S., Depping, R., Bruch, H., Thorns, C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4140 · Cited by 56
Incidence Patterns of Primary Bone Cancer in Taiwan (2003–2010): A Population-Based Study
Hung, G., Horng, J., Yen, H., Yen, C., Chen, W., Chen, P. C.-H., Wu, H.-T. H., & Chiou, H. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3697-3 · Cited by 56
Epidemiology of Adolescents and Young Adults with Cancer in Europe
Désandes, E., & Stark, D. (2016) · Progress in tumor research · doi:10.1159/000447037 · Cited by 56
Li, Y., Yao, K., Lu, M., Zhang, W., Xiao, C., & Tu, C. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s140560 · Cited by 57
Gilsenan, A., Harding, A., Kellier‐Steele, N., Harris, D., Midkiff, K. D., & Andrews, E. B. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4604-8 · Cited by 56
Lin, R.-C., Yang, S., Chiou, H., Hsieh, S.-C., Wen, S.-H., Lu, K., & Hsieh, Y. (2019) · Cells · doi:10.3390/cells8111441 · Cited by 56
CXCR 4‐mediated osteosarcoma growth and pulmonary metastasis is suppressed by Micro RNA ‐613
Zhu, Y., Tang, L., Zhao, S., Sun, B., Cheng, L., Tang, Y., Luo, Z., Lin, Z., Zhu, J., Zhu, W., et al. (2018) · Cancer Science · doi:10.1111/cas.13653 · Cited by 55
Recent advances in drug delivery systems for osteosarcoma therapy and bone regeneration
Kortam, S., Lu, Z., & Zreiqat, H. (2024) · Communications Materials · doi:10.1038/s43246-024-00612-2 · Cited by 55
Park, G.-B., Kim, D., Kim, Y., Lee, H.-K., Kim, C.-W., & Hur, D. (2015) · International Journal of Oncology · doi:10.3892/ijo.2014.2721 · Cited by 54
Xu, Q., Li, Z., Peng, H., Sun, Z., Cheng, R.-L., Ye, Z., & Li, W. (2011) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b1000373 · Cited by 55
Incidence Trends in the Diagnosis of Giant Cell Tumor of Bone in Sweden Since 1958
Rockberg, J., Bach, B. A., Amelio, J., Hernandez, R. K., Sobocki, P., Engellau, J., Bauer, H. C. F., & Liede, A. (2015) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.o.00156 · Cited by 55
Miller, B. J., Gao, Y., & Duchman, K. R. (2017) · Cancer Epidemiology · doi:10.1016/j.canep.2017.05.017 · Cited by 55
Zhou, Y. L., Yin, L., Li, H., Liu, L., & Xiao, T. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1598766 · Cited by 55
Osteosarcoma in Pediatric and Adult Populations: Are Adults Just Big Kids?
Kim, C., Davis, L. E., Albert, C. M., Samuels, B. L., Roberts, J. L., & Wagner, M. J. (2023) · Cancers · doi:10.3390/cancers15205044 · Cited by 54
Wang, T., Ji, F., Dai, Z., Xie, Y., & Yuan, D. (2015) · Cancer Biomarkers · doi:10.3233/cbm-150493 · Cited by 54
Anfinsen, K. P., Grotmol, T., Bruland, Ø. S., & Jónasdóttir, T. J. (2011) · Europe PMC (PubMed Central) · Cited by 54
Wilne, S., & Walker, D. (2010) · Archives of Disease in Childhood Education & Practice · doi:10.1136/adc.2008.143214 · Cited by 54
Cheng, G., Gao, F., Sun, X., Bi, H., & Zhu, Y. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5663 · Cited by 54
Senerchia, A. A., Macedo, C. R. P. D., Ferman, S., Scopinaro, M. J., Cacciavillano, W., Boldrini, É., Moraes, V. L., Rey, G., de Oliveira, C. T., Castillo, L. A., et al. (2016) · Cancer · doi:10.1002/cncr.30411 · Cited by 54
Nørregaard, K. S., Jürgensen, H. J., Gårdsvoll, H., Engelholm, L. H., Behrendt, N., & Søe, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136865 · Cited by 56
Evodiamine inhibits the proliferation of human osteosarcoma cells by blocking PI3K/Akt signaling
Meng, Z., WU, N., Liu, Y., Shu, K.-J., ZOU, X., Zhang, R., Pi, C.-J., He, B., Ke, Z., Chen, L., et al. (2015) · Oncology Reports · doi:10.3892/or.2015.4084 · Cited by 53
Lu, K., Yang, H., Su, C., Lue, K., Yang, S., & Hsieh, Y. (2012) · Food and Chemical Toxicology · doi:10.1016/j.fct.2012.11.019 · Cited by 53
Pereira, B. P., Zhou, Y., Gupta, A., Leong, D. T., Aung, K. Z., Ling, L., Pho, R. W. H., Galindo, M. A., Salto‐Tellez, M., Stein, G. S., et al. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21921 · Cited by 56
Metadata
- Authors
- Mirabello, L., Troisi, R. J., & Savage, S. A.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Savage, Sharon A.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2009-02-05
- Volume
- 115
- Issue
- 7
- Pages
- 1531-1543
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- PMC
- PMC2813207
- OpenAlex
- W1988325237
- Cited by
- 2,199
- References
- 52
- Citations by year
- 2026: 114 · 2025: 138 · 2024: 166 · 2023: 167 · 2022: 161 · 2021: 194 · 2020: 201 · 2019: 162 · 2018: 172 · 2017: 142 · 2016: 151 · 2015: 129 · 2014: 106 · 2013: 72 · 2012: 52
- FWCI
- 33.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (Z01CP010142)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Keywords
- osteosarcoma, incidence, survival rate, age differences, Paget disease, secondary malignancies, elderly patients, disease stage, SEER, bone tumors, mortality trends
- MeSH terms
- Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Bone Neoplasms, Child, Child, Preschool, Ethnicity, Female, Humans, Infant, Infant, Newborn, Male, Middle Aged, Osteosarcoma, Sex Factors, Survival Rate, SEER Program
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
